S 3304: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 10718956 |
| CHEMBL ID | 297792 |
| SCHEMBL ID | 2380826 |
| MeSH ID | M0489577 |
| Synonym |
|---|
| s-3304 , |
| s 3304 |
| CHEMBL297792 , |
| bdbm50063129 |
| (r)-3-(1h-indol-3-yl)-2-(5-p-tolylethynyl-thiophene-2-sulfonylamino)-propionic acid |
| 203640-27-1 |
| bk459f050x , |
| unii-bk459f050x |
| d-tryptophan, n-((5-((4-methylphenyl)ethynyl)-2-thienyl)sulfonyl)- |
| d-tryptophan, n-((5-(2-(4-methylphenyl)ethynyl)-2-thienyl)sulfonyl)- |
| s 3304 [who-dd] |
| YWCLDDLVLSQGSZ-JOCHJYFZSA-N |
| SCHEMBL2380826 |
| DTXSID20174292 |
| AKOS030593350 |
| DB12149 |
| CS-0027075 |
| HY-106992 |
| ((5-(p-tolylethynyl)thiophen-2-yl)sulfonyl)-d-tryptophan |
| d-tryptophan, n-[[5-[2-(4-methylphenyl)ethynyl]-2-thienyl]sulfonyl]- |
| DS-19841 |
| (r)-3-(1h-indol-3-yl)-2-(5-(p-tolylethynyl)thiophene-2-sulfonamido)propanoic acid |
| Q27274720 |
| C73841 |
| A908592 |
| GLXC-26541 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " Adverse events reported in the multiple dose treatment with S-3304 or placebo were mostly of mild severity, except for two episodes of moderate headache and two episodes of moderate myalgia." | ( Safety, tolerability and pharmacokinetics of oral S-3304, a novel matrix metalloproteinase inhibitor, in single and multiple dose escalation studies in healthy volunteers. Kambayashi, Y; Sollie, F; van Marle, S; van Vliet, A; Yamada-Sawada, T, 2005) | 0.33 |
| " Tolerance was based on subjective adverse events, clinical examination, vital signs, ECG and laboratory tests including haematology and biochemistry profiles using CTC grading." | ( Pharmacokinetics and safety assessments of high-dose and 4-week treatment with S-3304, a novel matrix metalloproteinase inhibitor, in healthy volunteers. Amin, DM; Bradford, D; Kambayashi, Y; Mant, TG; Pisupati, J; Tanaka, K; Yamada-Sawada, T; Yano, Y, 2007) | 0.34 |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Interstitial collagenase | Homo sapiens (human) | IC50 (µMol) | 1.0000 | 0.0002 | 0.8502 | 10.0000 | AID109225 |
| Neprilysin | Rattus norvegicus (Norway rat) | IC50 (µMol) | 1.0000 | 0.0010 | 0.1702 | 2.3000 | AID147399 |
| 72 kDa type IV collagenase | Homo sapiens (human) | IC50 (µMol) | 0.0108 | 0.0000 | 1.2848 | 10.0000 | AID107154; AID107334 |
| Stromelysin-1 | Homo sapiens (human) | IC50 (µMol) | 1.0000 | 0.0000 | 1.1484 | 10.0000 | AID107687 |
| Matrilysin | Homo sapiens (human) | IC50 (µMol) | 1.0000 | 0.0014 | 2.0859 | 10.0000 | AID107845 |
| Angiotensin-converting enzyme | Homo sapiens (human) | IC50 (µMol) | 1.0000 | 0.0001 | 0.5336 | 10.0000 | AID38861 |
| Matrix metalloproteinase-9 | Homo sapiens (human) | IC50 (µMol) | 0.0163 | 0.0000 | 0.7053 | 10.0000 | AID108020; AID108305 |
| Endothelin-converting enzyme 1 | Homo sapiens (human) | IC50 (µMol) | 1.0000 | 0.0120 | 0.5678 | 2.0000 | AID67193 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID147399 | Inhibitory activity against neutral endopeptidase (NEP) | 1998 | Journal of medicinal chemistry, Feb-12, Volume: 41, Issue:4 | Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives. |
| AID107845 | Inhibitory activity against Matrix metalloprotease-7 | 1998 | Journal of medicinal chemistry, Feb-12, Volume: 41, Issue:4 | Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives. |
| AID38861 | Inhibitory activity against Angiotensin I converting enzyme | 1998 | Journal of medicinal chemistry, Feb-12, Volume: 41, Issue:4 | Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives. |
| AID109225 | Inhibitory activity against Matrix metalloprotease-1 | 1998 | Journal of medicinal chemistry, Feb-12, Volume: 41, Issue:4 | Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives. |
| AID107687 | Inhibitory activity against Matrix metalloprotease-3 | 1998 | Journal of medicinal chemistry, Feb-12, Volume: 41, Issue:4 | Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives. |
| AID108020 | Inhibitory activity against human gelatinase B (Matrix metalloprotease-9) | 1998 | Journal of medicinal chemistry, Feb-12, Volume: 41, Issue:4 | Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives. |
| AID67193 | Inhibitory activity against endothelin converting enzyme (ECE) | 1998 | Journal of medicinal chemistry, Feb-12, Volume: 41, Issue:4 | Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives. |
| AID14252 | Maximum plasma concentration (Cmax) after p.o. administration of 200 mg/kg in mice | 1998 | Journal of medicinal chemistry, Feb-12, Volume: 41, Issue:4 | Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives. |
| AID107334 | Inhibitory activity against Matrix metalloprotease-2 (concentration required for 50% inhibition of enzyme activity) | 1999 | Journal of medicinal chemistry, May-20, Volume: 42, Issue:10 | Homology modeling of gelatinase catalytic domains and docking simulations of novel sulfonamide inhibitors. |
| AID108305 | Inhibitory activity against Matrix metalloprotease-9 (concentration required for 50% inhibition of enzyme activity) | 1999 | Journal of medicinal chemistry, May-20, Volume: 42, Issue:10 | Homology modeling of gelatinase catalytic domains and docking simulations of novel sulfonamide inhibitors. |
| AID107154 | Inhibitory activity against human gelatinase A (matrix metalloprotease-2 MMP2) | 1998 | Journal of medicinal chemistry, Feb-12, Volume: 41, Issue:4 | Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (33.33) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (17.33) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 3 (50.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 3 (50.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase I Study of S-3304 in Patients With Solid Tumors [NCT00033566] | Phase 1 | 0 participants | Interventional | 2001-10-31 | Completed | ||
| A Phase 1 Study of S-3304 in Patients With Solid Tumors [NCT00033215] | Phase 1 | 32 participants (Actual) | Interventional | 2001-11-30 | Completed | ||
| A Phase I/II Study of the Safety, Pharmacokinetic Interaction and Efficacy of S-3304 in Combination With Standard Therapy in Patients With Locally Advanced Non-small Cell Lung Cancer. [NCT00078390] | Phase 1/Phase 2 | 9 participants (Actual) | Interventional | 2003-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||